Rx Mobile Devices Promos: Benefits Often More Prominent Than Risks
Executive Summary
In an analysis of direct-to-consumer mobile promotions, FDA found that risks and benefits are not equally prominent and accessible in the communications and their landing pages.
You may also be interested in...
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
Contrave TV Ad's Slimmed Down Adverse Events Draw FDA Rebuke
Referencing opioids and suicidal thoughts is not sufficient, US regulators say; letter comes as Orexigen has seen an upsurge in Contrave prescriptions.
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.